Warren C. Swegal, MD, discusses the safety and tolerability of tyrosine kinase inhibitors for patients with radioactive iodine–refractory differentiated thyroid cancer.
Warren C. Swegal, MD, a head and neck cancer surgeon at Allegheny Health Network, discusses the safety and tolerability of tyrosine kinase inhibitors (TKIs) for patients with radioactive iodine (RAI)–refractory differentiated thyroid cancer (DTC).
TKIs including sorafenib (Nexavar), lenvatinib (Lenvima), and cabozantinib (Cabometyx) can be used to treat patients with RAI-refractory DTC if the disease is metastatic or not resectable. Lenvatinib is the preferred option with category 1 evidence according to the National Comprehensive Cancer Network.
Swegal says that TKIs are generally considered to have better toxicity profiles than standard chemotherapy drugs. Important adverse events (AEs) to watch for with TKIs include gastrointestinal (GI) AEs such as diarrhea. Hypertension of any grade has occurred in 70% to 75% of patients in clinical trials of TKIs such as the SELECT trial (NCT01321554) investigating lenvatinib.
Other frequently occurring AEs of note include weight loss secondary to anorexia and hand-foot skin reactions. These are primarily grade 1 and 2 AEs that can be resolved with dose modification, and rarely occur at higher grades. Other common AEs to be aware of include alopecia and mucositis, although they are less frequent, according to Swegal.
TRANSCRIPTION:
0:08 | In general, TKIs are considered safer than standard chemotherapy drugs, which can have a lot of significant toxicities. That being said, there are some important things you need think about with regard to TKIs. GI [AEs] are pretty common, things like diarrhea or GI complaints. Hypertension is very common. Again, [it is] sometimes up to 70% to 75% of patients depending on the study you read. Things like weight loss secondary to anorexia can be seen in a significant portion of patients, and then you can also have some hand-foot skin reactions with some of these medications. That can vary with regard to grade. Most of these are grade 1 or grade 2 toxicities, not terribly serious, that resolve with some dose adjustment and are much less likely to be grade 3 or grade 4. I do also have to say alopecia and mucositis are also possibilities to be aware of as well.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
No Improvement With Durvalumab vs Cetuximab in Advanced HNSCC
January 9th 2025The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck squamous cell carcinoma undergoing radiotherapy with contraindications to cisplatin, leading to early trial closure.
Read More